Blood-based Biomarker For Sports Medicine Market Size, Share & Trends Analysis Report By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP), By Region, And Segment Forecasts, 2024 - 2030
Blood-Based Biomarker For Sports Medicine Market Growth & Trends
The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.
The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.
Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.
Blood-Based Biomarker For Sports Medicine Market Report Highlights
- The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery
- Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings
- In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Regional scope
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Blood-based Biomarker for Sports Medicine Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing Demand for Personalized Medicine
- 3.2.1.2. Increased Focus on Injury Prevention and Recovery
- 3.2.1.3. Growing R&D and Rising Investments in Sports Medicine s
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory Challenges and Lack of Awareness & Standardization
- 3.3. Blood-based Biomarker for Sports Medicine Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
- Chapter 4. Blood-based Biomarker for Sports Medicine Market: Type Estimates & Trend Analysis
- 4.1. Global Blood-based Biomarker for Sports Medicine Market: Type Dashboard
- 4.2. Global Blood-based Biomarker for Sports Medicine Market: Type Movement Analysis
- 4.3. Global Blood-based Biomarker for Sports Medicine Market by Type, Revenue
- 4.4. CK
- 4.4.1. CK market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5. Myoglobin
- 4.5.1. Myoglobin market estimates and forecasts 2018 - 2030 (USD Million)
- 4.6. Lactate
- 4.6.1. Lactate market estimates and forecasts 2018 - 2030 (USD Million)
- 4.7. WBC
- 4.7.1. WBC market estimates and forecasts 2018 - 2030 (USD Million)
- 4.8. Urea
- 4.8.1. Urea market estimates and forecasts 2018 - 2030 (USD Million)
- 4.9. CRP
- 4.9.1. CRP market estimates and forecasts 2018 - 2030 (USD Million)
- 4.10. Lipid and Protein Hydroperoxides
- 4.10.1. Lipid and protein hydroperoxides market estimates and forecasts 2018 - 2030 (USD Million)
- 4.11. IL-6
- 4.11.1. IL-6 market estimates and forecasts 2018 - 2030 (USD Million)
- 4.12. Others
- 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 5. Blood-based Biomarker for Sports Medicine Market: Regional Estimates & Trend Analysis by Type
- 5.1. Regional Dashboard
- 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 5.3. North America
- 5.3.1. U.S.
- 5.3.1.1. Key country dynamics
- 5.3.1.2. Regulatory framework/ reimbursement structure
- 5.3.1.3. Competitive scenario
- 5.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 5.3.2. Canada
- 5.3.2.1. Key country dynamics
- 5.3.2.2. Regulatory framework/ reimbursement structure
- 5.3.2.3. Competitive scenario
- 5.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 5.3.3. Mexico
- 5.3.3.1. Key country dynamics
- 5.3.3.2. Regulatory framework/ reimbursement structure
- 5.3.3.3. Competitive scenario
- 5.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4. Europe
- 5.4.1. UK
- 5.4.1.1. Key country dynamics
- 5.4.1.2. Regulatory framework/ reimbursement structure
- 5.4.1.3. Competitive scenario
- 5.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.2. Germany
- 5.4.2.1. Key country dynamics
- 5.4.2.2. Regulatory framework/ reimbursement structure
- 5.4.2.3. Competitive scenario
- 5.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.3. France
- 5.4.3.1. Key country dynamics
- 5.4.3.2. Regulatory framework/ reimbursement structure
- 5.4.3.3. Competitive scenario
- 5.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.4. Italy
- 5.4.4.1. Key country dynamics
- 5.4.4.2. Regulatory framework/ reimbursement structure
- 5.4.4.3. Competitive scenario
- 5.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.5. Spain
- 5.4.5.1. Key country dynamics
- 5.4.5.2. Regulatory framework/ reimbursement structure
- 5.4.5.3. Competitive scenario
- 5.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.6. Norway
- 5.4.6.1. Key country dynamics
- 5.4.6.2. Regulatory framework/ reimbursement structure
- 5.4.6.3. Competitive scenario
- 5.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.7. Sweden
- 5.4.7.1. Key country dynamics
- 5.4.7.2. Regulatory framework/ reimbursement structure
- 5.4.7.3. Competitive scenario
- 5.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 5.4.8. Denmark
- 5.4.8.1. Key country dynamics
- 5.4.8.2. Regulatory framework/ reimbursement structure
- 5.4.8.3. Competitive scenario
- 5.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5. Asia Pacific
- 5.5.1. Japan
- 5.5.1.1. Key country dynamics
- 5.5.1.2. Regulatory framework/ reimbursement structure
- 5.5.1.3. Competitive scenario
- 5.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.2. China
- 5.5.2.1. Key country dynamics
- 5.5.2.2. Regulatory framework/ reimbursement structure
- 5.5.2.3. Competitive scenario
- 5.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.3. India
- 5.5.3.1. Key country dynamics
- 5.5.3.2. Regulatory framework/ reimbursement structure
- 5.5.3.3. Competitive scenario
- 5.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.4. Australia
- 5.5.4.1. Key country dynamics
- 5.5.4.2. Regulatory framework/ reimbursement structure
- 5.5.4.3. Competitive scenario
- 5.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.5. New Zealand
- 5.5.5.1. Key country dynamics
- 5.5.5.2. Regulatory framework/ reimbursement structure
- 5.5.5.3. Competitive scenario
- 5.5.5.4. New Zealand market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.6. Taiwan
- 5.5.6.1. Key country dynamics
- 5.5.6.2. Regulatory framework/ reimbursement structure
- 5.5.6.3. Competitive scenario
- 5.5.6.4. Taiwan market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.7. Hong Kong
- 5.5.7.1. Key country dynamics
- 5.5.7.2. Regulatory framework/ reimbursement structure
- 5.5.7.3. Competitive scenario
- 5.5.7.4. Hong Kong market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.8. Singapore
- 5.5.8.1. Key country dynamics
- 5.5.8.2. Regulatory framework/ reimbursement structure
- 5.5.8.3. Competitive scenario
- 5.5.8.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.9. Thailand
- 5.5.9.1. Key country dynamics
- 5.5.9.2. Regulatory framework/ reimbursement structure
- 5.5.9.3. Competitive scenario
- 5.5.9.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.10. Vietnam
- 5.5.10.1. Key country dynamics
- 5.5.10.2. Regulatory framework/ reimbursement structure
- 5.5.10.3. Competitive scenario
- 5.5.10.4. Vietnam market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6. Latin America
- 5.6.1. Brazil
- 5.6.1.1. Key country dynamics
- 5.6.1.2. Regulatory framework/ reimbursement structure
- 5.6.1.3. Competitive scenario
- 5.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.2. Argentina
- 5.6.2.1. Key country dynamics
- 5.6.2.2. Regulatory framework/ reimbursement structure
- 5.6.2.3. Competitive scenario
- 5.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.3. Chile
- 5.6.3.1. Key country dynamics
- 5.6.3.2. Regulatory framework/ reimbursement structure
- 5.6.3.3. Competitive scenario
- 5.6.3.4. Chile market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7. MEA
- 5.7.1. South Africa
- 5.7.1.1. Key country dynamics
- 5.7.1.2. Regulatory framework/ reimbursement structure
- 5.7.1.3. Competitive scenario
- 5.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.2. Saudi Arabia
- 5.7.2.1. Key country dynamics
- 5.7.2.2. Regulatory framework/ reimbursement structure
- 5.7.2.3. Competitive scenario
- 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.3. UAE
- 5.7.3.1. Key country dynamics
- 5.7.3.2. Regulatory framework/ reimbursement structure
- 5.7.3.3. Competitive scenario
- 5.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.4. Egypt
- 5.7.4.1. Key country dynamics
- 5.7.4.2. Regulatory framework/ reimbursement structure
- 5.7.4.3. Competitive scenario
- 5.7.4.4. Egypt market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.5. Qatar
- 5.7.5.1. Key country dynamics
- 5.7.5.2. Regulatory framework/ reimbursement structure
- 5.7.5.3. Competitive scenario
- 5.7.5.4. Qatar market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 6. Competitive Landscape
- 6.1. Company/Competition Categorization
- 6.2. Vendor Landscape
- 6.2.1. List of key distributors and channel partners
- 6.2.2. Key customers
- 6.2.3. Key company market share analysis, 2023
- 6.2.4. Abbott
- 6.2.4.1. Company overview
- 6.2.4.2. Financial performance
- 6.2.4.3. Product benchmarking
- 6.2.4.4. Strategic initiatives
- 6.2.5. BIOMÉRIEUX
- 6.2.5.1. Company overview
- 6.2.5.2. Financial performance
- 6.2.5.3. Product benchmarking
- 6.2.5.4. Strategic initiatives
- 6.2.6. F. Hoffmann-La Roche Ltd.
- 6.2.6.1. Company overview
- 6.2.6.2. Financial performance
- 6.2.6.3. Product benchmarking
- 6.2.6.4. Strategic initiatives
- 6.2.7. ARUP Laboratories
- 6.2.7.1. Company overview
- 6.2.7.2. Financial performance
- 6.2.7.3. Product benchmarking
- 6.2.7.4. Strategic initiatives
- 6.2.8. Siemens Healthineers AG
- 6.2.8.1. Company overview
- 6.2.8.2. Financial performance
- 6.2.8.3. Product benchmarking
- 6.2.8.4. Strategic initiatives
- 6.2.9. RayBiotech, Inc.
- 6.2.9.1. Company overview
- 6.2.9.2. Financial performance
- 6.2.9.3. Product benchmarking
- 6.2.9.4. Strategic initiatives
- 6.2.10. Thermo Fisher Scientific, Inc.
- 6.2.10.1. Company overview
- 6.2.10.2. Financial performance
- 6.2.10.3. Product benchmarking
- 6.2.10.4. Strategic initiatives
- 6.2.11. Bio-Rad Laboratories, Inc.
- 6.2.11.1. Company overview
- 6.2.11.2. Financial performance
- 6.2.11.3. Product benchmarking
- 6.2.11.4. Strategic initiatives
- 6.2.12. Beckman Coulter, Inc.
- 6.2.12.1. Company overview
- 6.2.12.2. Financial performance
- 6.2.12.3. Product benchmarking
- 6.2.12.4. Strategic initiatives
- 6.2.13. Randox Laboratories Ltd.
- 6.2.13.1. Company overview
- 6.2.13.2. Financial performance
- 6.2.13.3. Product benchmarking
- 6.2.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook